Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.

Abstract

The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis is not established after reduced intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) from fully matched donors. This was a randomized, open-label, multicenter, phase 2 trial. All patients received a RIC regimen with fludarabine, intravenous busulfan for 2 days (Flu-Bu2), and a peripheral blood stem cell (PBSC) graft from a matched related or 10/10 HLA-matched unrelated donor. Patients were randomly assigned to receive anti-thymocyte globulin (ATG) 5 mg/kg plus standard GVHD prophylaxis or PTCy 50 mg/kg/d at days +3 and +4 plus standard GVHD prophylaxis. The primary endpoint was the composite endpoint of GVHD- and relapse-free survival (GRFS) at 12 months after HSCT. Eighty-nine patients were randomly assigned to receive either PTCy or control prophylaxis with ATG. At 12 months, disease-free survival was 65.9% in the PTCy group and 67.6% in the ATG group (P = 0.99). Cumulative incidence of relapse, non-relapse mortality, and overall survival were also comparable in the two groups. GRFS at 12 months was 54.5% in the PTCy group versus 43.2% in the ATG group (P = 0.27). The median time to neutrophil and platelet count recovery was significantly longer in the PTCy group compared to the ATG group. Except for day +30, where EORTC QLQ-C30 scores were significantly lower in the PTCy compared to the ATG group, the evolution with time was not different between the two groups. Although the primary objective was not met, PTCy is effective for GVHD prophylaxis in patients receiving Flu-Bu2 conditioning with a PBSC graft from a fully matched donor and was well tolerated in term of adverse events and quality of life. This trial was registered at clinicaltrials.gov: NCT02876679.

• Authors: Eolia Brissot, Myriam Labopin, Helene Labussière, Gaelle Fossard, Patrice Chevallier, Thierry Guillaume, Ibrahim Yakoub-Agha, Micha Srour, Claude-Eric Bulabois, Anne Huynh, Sylvain Chantepie, Anne-Lise Menard, Marie-Therese Rubio, Patrice Ceballos, Rémy Dulery, Sabine Furst, Florent Malard, Didier Blaise, Mohamad Mohty
• Journal: Blood cancer journal (Blood Cancer J) Vol. 14 Issue 1 Pg. 31 (02 19 2024) ISSN: 2044-5385 [Electronic] United States
• PMID: 38374026 (Publication Type: Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2024. The Author(s).

Chemical References

• Antilymphocyte Serum
• Cyclophosphamide

Topics

• Humans
• Antilymphocyte Serum (therapeutic use)
• Unrelated Donors
• Siblings
• Quality of Life
• Cyclophosphamide (therapeutic use)
• Hematopoietic Stem Cell Transplantation (adverse effects)
• Graft vs Host Disease (etiology, prevention & control)
• Retrospective Studies